CureVac NV Net Income
| CVAC Stock | USD 4.66 0.00 0.00% |
As of the 2nd of February, CureVac NV shows the Mean Deviation of 1.22, standard deviation of 2.35, and Risk Adjusted Performance of (0.05). CureVac NV technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
CureVac NV Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.2313 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 186.5 M | 195.8 M | |
| Net Loss | -370.5 M | -352 M | |
| Net Income | 219.5 M | 230.5 M | |
| Net Income Per Share | 0.65 | 0.68 | |
| Net Income Per E B T | 0.98 | 1.08 |
CureVac | Net Income | Build AI portfolio with CureVac Stock |
Analyzing CureVac NV's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing CureVac NV's current valuation and future prospects.
Latest CureVac NV's Net Income Growth Pattern
Below is the plot of the Net Income of CureVac NV over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in CureVac NV financial statement analysis. It represents the amount of money remaining after all of CureVac NV operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is CureVac NV's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CureVac NV's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 190.88 M | 10 Years Trend |
|
Net Income |
| Timeline |
CureVac Net Income Regression Statistics
| Arithmetic Mean | (73,322,853) | |
| Geometric Mean | 114,250,407 | |
| Coefficient Of Variation | (210.06) | |
| Mean Deviation | 92,146,439 | |
| Median | (71,241,000) | |
| Standard Deviation | 154,023,820 | |
| Sample Variance | 23723.3T | |
| Range | 607.6M | |
| R-Value | 0.20 | |
| Mean Square Error | 24267.3T | |
| R-Squared | 0.04 | |
| Significance | 0.44 | |
| Slope | 6,176,436 | |
| Total Sum of Squares | 379573.4T |
CureVac Net Income History
Other Fundumenentals of CureVac NV
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
CureVac NV Net Income component correlations
CureVac Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for CureVac NV is extremely important. It helps to project a fair market value of CureVac Stock properly, considering its historical fundamentals such as Net Income. Since CureVac NV's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CureVac NV's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CureVac NV's interrelated accounts and indicators.
Click cells to compare fundamentals
Search Suggestions
| CV | CapsoVision Common Stock | Company |
| CVAIX | Calamos Opportunistic Value | Mutual Fund |
| CVY | Invesco Zacks Multi Asset | ETF |
| CVX | Convex Finance | Cryptocurrency |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionCureVac Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, CureVac NV reported net income of 190.88 M. This is 44.07% lower than that of the Biotechnology sector and 172.51% higher than that of the Health Care industry. The net income for all United States stocks is 66.57% higher than that of the company.
CureVac Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CureVac NV's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CureVac NV could also be used in its relative valuation, which is a method of valuing CureVac NV by comparing valuation metrics of similar companies.CureVac NV is currently under evaluation in net income category among its peers.
CureVac NV Current Valuation Drivers
We derive many important indicators used in calculating different scores of CureVac NV from analyzing CureVac NV's financial statements. These drivers represent accounts that assess CureVac NV's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CureVac NV's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 5.6B | 1.1B | 839.8M | 738.9M | 849.7M | 807.2M | |
| Enterprise Value | 4.8B | 611.0M | 479.1M | 296.1M | 340.5M | 323.5M |
CureVac NV ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CureVac NV's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CureVac NV's managers, analysts, and investors.Environmental | Governance | Social |
CureVac NV Institutional Holders
Institutional Holdings refers to the ownership stake in CureVac NV that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of CureVac NV's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CureVac NV's value.| Shares | Ubs Group Ag | 2025-06-30 | 242.1 K | Deutsche Bank Ag | 2025-06-30 | 215.1 K | D. E. Shaw & Co Lp | 2025-06-30 | 206.4 K | Ubs Asset Mgmt Americas Inc | 2025-06-30 | 201.3 K | Swiss National Bank | 2025-06-30 | 193.6 K | Forsta Ap-fonden | 2025-06-30 | 156.3 K | Freestone Capital Holdings, Llc | 2025-06-30 | 144.1 K | Jane Street Group Llc | 2025-06-30 | 138.6 K | State Of Wyoming | 2025-06-30 | 138.3 K | Eckert Corp | 2025-06-30 | 2 M | Qube Research & Technologies | 2025-06-30 | 1.2 M |
CureVac Fundamentals
| Return On Equity | 0.4 | ||||
| Return On Asset | 0.24 | ||||
| Profit Margin | 1.82 % | ||||
| Operating Margin | 5.73 % | ||||
| Current Valuation | 599.28 M | ||||
| Shares Outstanding | 225.17 M | ||||
| Shares Owned By Insiders | 0.09 % | ||||
| Shares Owned By Institutions | 10.43 % | ||||
| Number Of Shares Shorted | 547.32 K | ||||
| Price To Book | 1.03 X | ||||
| Price To Sales | 14.83 X | ||||
| Revenue | 535.18 M | ||||
| Gross Profit | 65.99 M | ||||
| EBITDA | 209.69 M | ||||
| Net Income | 190.88 M | ||||
| Cash And Equivalents | 540.87 M | ||||
| Cash Per Share | 2.85 X | ||||
| Total Debt | 38.97 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.61 X | ||||
| Book Value Per Share | 5.63 X | ||||
| Cash Flow From Operations | 101.85 M | ||||
| Short Ratio | 0.32 X | ||||
| Earnings Per Share | 0.67 X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 5.41 | ||||
| Number Of Employees | 825 | ||||
| Beta | 1.84 | ||||
| Market Capitalization | 1.05 B | ||||
| Total Asset | 802.83 M | ||||
| Retained Earnings | (1.4 B) | ||||
| Working Capital | 454.07 M | ||||
| Net Asset | 802.83 M |
About CureVac NV Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CureVac NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CureVac NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CureVac NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CureVac NV offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CureVac NV's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Curevac Nv Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Curevac Nv Stock:Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Biotechnology sector continue expanding? Could CureVac diversify its offerings? Factors like these will boost the valuation of CureVac NV. Projected growth potential of CureVac fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CureVac NV data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.24 | Earnings Share 0.67 | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between CureVac NV's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CureVac NV should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, CureVac NV's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.